A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

ClinicalTrials.gov ID: NCT05623020

Public ClinicalTrials.gov record NCT05623020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 26, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Study identification

NCT ID: NCT05623020
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Pfizer; Industry
Enrollment: 1,116 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Elranatamab Drug
Daratumumab Drug
Lenalidomide Drug
Dexamethasone Drug
Bortezomib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 9, 2022
Primary completion: Oct 17, 2030
Completion: Oct 2, 2033
Last update posted: Jun 22, 2026

2022 – 2033

United States locations

U.S. sites: 11
U.S. states: 4
U.S. cities: 9

Facility	City	State	ZIP	Site status
Jupiter Medical Center/Anderson Family Cancer Institute	Jupiter	Florida	33458	Not yet recruiting
MSK Basking Ridge	Basking Ridge	New Jersey	07920	Recruiting
MSK Monmouth	Middletown	New Jersey	07748	Recruiting
MSK Bergen	Montvale	New Jersey	07645	Recruiting
MSK Commack	Commack	New York	11725	Recruiting
MSK Westchester	Harrison	New York	10604	Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York	New York	10021	Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus	New York	New York	10065	Recruiting
Memorial Sloan Kettering Cancer Center-Main Campus	New York	New York	10065	Recruiting
MSK Nassau	Uniondale	New York	11553	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05623020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 22, 2026 · Synced Jun 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05623020 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →